Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Asensus Surgical, Inc. (ASXC)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
0.9136-0.0168 (-1.81%)
At close: 04:00PM EST
0.9400 +0.03 (+2.89%)
After hours: 07:58PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.9304
Open0.9200
Bid0.9200 x 800
Ask0.9400 x 1000
Day's Range0.8600 - 0.9300
52 Week Range0.8600 - 6.9500
Volume2,749,272
Avg. Volume3,985,203
Market Cap214.879M
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-0.3110
Earnings DateMar 09, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ASXC

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Asensus Surgical, Inc.
    Analyst Report: Intuitive Surgical, Inc.Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 6,000 da Vinci systems in hospitals worldwide, with nearly 4,000 installations in the United States and a growing number in emerging markets.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • Business Wire

    Asensus Surgical Provides Preliminary 2021 Year-End Corporate Update

    RESEARCH TRIANGLE PARK, N.C., January 10, 2022--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today provided a preliminary 2021 year-end corporate update.

  • Business Wire

    Asensus Surgical to Participate in the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright Bioconnect 2022 Conference

    RESEARCH TRIANGLE PARK, N.C., December 29, 2021--Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the 40th Annual J.P. Morgan Healthcare Conference. The Company’s virtual presentation will take place on Thursday, January 13, 2022 at 9:00 am Eastern Time.

  • Business Wire

    Asensus Surgical Announces Purchase of Senhance Robotic System by RZD Medicine

    RESEARCH TRIANGLE PARK, N.C., November 29, 2021--Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced Private Healthcare Institution Railway Clinical Hospital RZD Medicine of Rostov-on-Don ("RZD Medicine"), located in Rostov, Russia, has initiated its Senhance® Robotic Surgery program following the purchase of a Senhance Surgical System.

Advertisement
Advertisement